Mytos secures £15m in Series A funding from Buckley Ventures, IQ Capital and Wing VC to scale automated cell production.
The round was led by Buckley Ventures and will fund manufacturing and distribution scale-up.
Mytos develops automated systems for human cell manufacturing to support drug development and life sciences research. The company is based in London, UK.
Mytos has secured £15m in Series A funding led by Buckley Ventures, with participation from IQ Capital and Wing VC. The fresh capital will be deployed to accelerate manufacturing and distribution of its automated cell production systems to biotech and pharma firms, alongside expanding its development and sales teams.
The company has created a platform designed to automate human cell production, addressing a major bottleneck in drug discovery where manual culture methods consume considerable time and introduce experimental variability. The technology integrates tasks such as imaging and media replenishment into a unified workflow, allowing scientists to monitor progress remotely.
Following this latest round of financing, the firm intends to scale its reach across the life sciences sector and move into cell therapy manufacturing. The funding package follows sustained demand from global laboratories seeking alternatives to manual cell culture.
From the founder
"The most tedious process in biotech is growing human cells by hand. Every scientist needs to spend hours a day growing cells and coming in on weekends to look after them,"
Ali Afshar
CEO & Co-Founder at Mytos
Investor perspective
"Mytos is revolutionizing cell manufacturing, providing a simple solution that pharma and biotech companies can easily integrate into their research workflow,"
Jonathan Choi
Partner, Buckley Ventures
Use of funds
- 01Continue product development
- 02Invest in sales and marketing
